Press releases

Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the LOTUS Edge™ Valve System, the company's next generation transcatheter aortic valve implantation (TAVI) technology. The...

Boston Scientific Corporation (NYSE: BSX) will participate in the Morgan Stanley Global Healthcare Conference on September 13, in New York City. Mike Mahoney, chief executive officer, and Dan...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Wells Fargo Healthcare Conference on September 7, in Boston. Mike Mahoney, chief executive officer, Dan Brennan,...

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 36th Annual Canaccord Genuity Growth Conference on August 11 in Boston and the 2016 Wedbush PacGrow Healthcare...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.126 billion during the second quarter ended June 30, 2016, compared to the company's guidance range for the quarter of $2.010 to...

Addition of leading radiofrequency ablation company expands therapeutic options for patients with chronic pain

CEO Mike Mahoney welcomes Fujimori as a business leader with “significant insights on how large companies plan, execute and compete globally.”

Boston Scientific will webcast its conference call with financial results and business highlights for Q2 ended June 30, 2016. Learn how to tune in.

Studies show that treatment is less costly and has lower hospital re-admissions

Accelerates momentum to bring differentiated value to patients and health care systems

Boston Scientific will participate in the healthcare conference on June 9, 2016. A live webcast and replay will be available.

Boston Scientific will participate in the healthcare investor conference on June 7, 2016. A live webcast and replay will be available.

Full-body MRI access expands spinal cord stimulation offering and brings customized therapy to more patients suffering from chronic pain

Key data to be presented include real-world outcomes with the with the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device in Europe

Late-breaker data presented at HRS scientific sessions is most extensive post-market study for S-ICD

New catheters and software enhancement expand capabilities of high-definition Rhythmia™ Mapping System

Boston Scientific will participate in the healthcare investor conference on May 12, 2016. A live webcast and replay will be available.

Boston Scientific (NYSE: BSX) today announced key data, including one late-breaking clinical trial, that will be featured at the 37th Annual Scientific Sessions of the Heart Rhythm Society (HRS)...

"This strong start enables us to raise our outlook for the year,” said Boston Scientific CEO Mike Mahoney

FDA approval includes ACCOLADE™ MRI and ESSENTIO™ MRI pacemakers and INGEVITY™ MRI pacing leads

Boston Scientific will participate in the healthcare investor conference on May 5, 2016. A live webcast and replay will be available.

European approval granted for third-generation system and all previously implanted, second-generation systems

No reports of patient injury or death; no risk to patients who previously underwent a thrombectomy with the Fetch 2 catheter

The company rejects the allegations in the petition to the Food and Drug Administration filed by a Texas-based law firm